Resumo

BUENO, F.; ABELLEIRA, E.; SMULEVER, A.  e  PITOIA, F.. Partial response to lenvatinib as a second line of treatment in advanced differentiated cancer of thyroid. Rev. argent. endocrinol. metab. [online]. 2018, vol.55, n.3, pp.61-70. ISSN 1851-3034.

Distant metastases occur in around 10% of patients with differentiated thyroid cancer (DTC), and half of these cases will become refractory to radioiodine therapy (RAIR). Sorafenib was the first multikinase inhibitor (MKI) approved by the FDA for patients with differentiated advanced and progressive RAIR thyroid cancer, and it is the only one approved by ANMAT in our country for this indication. Lenvatinib is the second MKI approved by the FDA for this group of patients, and is a therapeutic alternative that should be considered, due to its availability as a compassive use drug in our country. We present our experience with the use of lenvatinib as a second line of treatment in a patient with DTC with advanced and progressive disease under treatment with sorafenib.

Palavras-chave : Differentiated thyroid cancer; Radioiodine-refractory thyroid cancer; Sorafenib; Lenvatinib.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )